| Considerable escape of SARS-CoV-2 Omicron to antibody neutralization D Planas, N Saunders, P Maes, F Guivel-Benhassine, C Planchais, ... Nature 602 (7898), 671-675, 2022 | 1425 | 2022 |
| Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern L Vangeel, W Chiu, S De Jonghe, P Maes, B Slechten, J Raymenants, ... Antiviral research 198, 105252, 2022 | 396 | 2022 |
| Symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection by a phylogenetically distinct strain J Van Elslande, P Vermeersch, K Vandervoort, T Wawina-Bokalanga, ... Clinical Infectious Diseases 73 (2), 354-356, 2021 | 353 | 2021 |
| Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients J Van Elslande, E Houben, M Depypere, A Brackenier, S Desmet, ... Clinical Microbiology and Infection 26 (8), 1082-1087, 2020 | 287 | 2020 |
| Serum neutralization of SARS-CoV-2 Omicron sublineages BA. 1 and BA. 2 in patients receiving monoclonal antibodies T Bruel, J Hadjadj, P Maes, D Planas, A Seve, I Staropoli, ... Nature medicine 28 (6), 1297-1302, 2022 | 260 | 2022 |
| Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries J Creswell, AJ Codlin, E Andre, MA Micek, A Bedru, EJ Carter, RP Yadav, ... BMC infectious diseases 14, 1-12, 2014 | 218 | 2014 |
| A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region JCS Ngabonziza, C Loiseau, M Marceau, A Jouet, F Menardo, O Tzfadia, ... Nature communications 11 (1), 2917, 2020 | 174 | 2020 |
| Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study NA Makhado, E Matabane, M Faccin, C Pinçon, A Jouet, F Boutachkourt, ... The Lancet Infectious Diseases 18 (12), 1350-1359, 2018 | 152 | 2018 |
| Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs J Van Elslande, B Decru, S Jonckheere, E Van Wijngaerden, E Houben, ... Clinical Microbiology and Infection 26 (11), 1557. e1-1557. e7, 2020 | 144 | 2020 |
| The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis TM Walker, P Miotto, CU Köser, PW Fowler, J Knaggs, Z Iqbal, M Hunt, ... The Lancet Microbe 3 (4), e265-e273, 2022 | 138 | 2022 |
| Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection J Van Elslande, M Oyaert, S Ailliet, M Van Ranst, N Lorent, ... Journal of Clinical Virology 136, 104765, 2021 | 134 | 2021 |
| Resistance of Omicron subvariants BA. 2.75. 2, BA. 4.6, and BQ. 1.1 to neutralizing antibodies D Planas, T Bruel, I Staropoli, F Guivel-Benhassine, F Porrot, P Maes, ... Nature communications 14 (1), 824, 2023 | 130 | 2023 |
| The omicron (B. 1.1. 529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters R Abdelnabi, CS Foo, X Zhang, V Lemmens, P Maes, B Slechten, ... Antiviral research 198, 105253, 2022 | 124 | 2022 |
| Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria E André, L Goeminne, A Cabibbe, P Beckert, BK Mukadi, V Mathys, ... Clinical Microbiology and Infection 23 (3), 167-172, 2017 | 104 | 2017 |
| A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics of SARS-CoV-2 lineages S Dellicour, K Durkin, SL Hong, B Vanmechelen, J Martí-Carreras, MS Gill, ... Molecular biology and evolution 38 (4), 1608-1613, 2021 | 95 | 2021 |
| Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs A Jouet, C Gaudin, N Badalato, C Allix-Béguec, S Duthoy, A Ferré, ... European Respiratory Journal 57 (3), 2021 | 84 | 2021 |
| Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 in patients receiving monoclonal antibodies T Bruel, K Stéfic, Y Nguyen, D Toniutti, I Staropoli, F Porrot, ... Cell Reports Medicine 3 (12), 2022 | 53 | 2022 |
| Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection J Van Elslande, M Oyaert, N Lorent, YV Weygaerde, G Van Pottelbergh, ... Diagnostic Microbiology and Infectious Disease 103 (1), 115659, 2022 | 53 | 2022 |
| Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays E André, L Goeminne, A Colmant, P Beckert, S Niemann, M Delmée Clinical Microbiology and Infection 23 (4), 267. e5-267. e7, 2017 | 53 | 2017 |
| Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda JCS Ngabonziza, W Ssengooba, F Mutua, G Torrea, A Dushime, ... BMC infectious diseases 16, 1-7, 2016 | 53 | 2016 |
Marc Van RanstProfessor of Virology, University of LeuvenEmail verificata su uz.kuleuven.ac.be
